STAT+: Pharmalittle: We’re reading about payments to Russian middlemen, a possible Dupixent rival, and more

AI Summary

The article reports allegations that four major pharmaceutical companies paid tens of millions of dollars to intermediaries involved in supplying lifesaving medicines to Russian government entities. It also flags other pharmaceutical developments, including a potential competitor to Dupixent.

Four big drugmakers allegedly paid tens of millions of dollars to middlemen to supply lifesaving drugs to Russian government entities